Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Acquired by MPM Bioimpact LLC

MPM Bioimpact LLC lifted its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 109.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 459,943 shares of the biotechnology company’s stock after purchasing an additional 240,435 shares during the period. MPM Bioimpact LLC owned about 1.70% of Arcturus Therapeutics worth $7,805,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the stock. Franklin Resources Inc. boosted its holdings in Arcturus Therapeutics by 54.6% in the 3rd quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company’s stock worth $2,412,000 after buying an additional 36,714 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its position in shares of Arcturus Therapeutics by 139.7% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 82,057 shares of the biotechnology company’s stock valued at $1,393,000 after acquiring an additional 47,824 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Arcturus Therapeutics by 45.0% in the fourth quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 3,705 shares during the last quarter. Spire Wealth Management increased its position in shares of Arcturus Therapeutics by 393.3% during the fourth quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 10,746 shares in the last quarter. Finally, Empire Life Investments Inc. raised its position in shares of Arcturus Therapeutics by 85.5% in the fourth quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company’s stock valued at $4,742,000 after buying an additional 128,771 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Trading Up 2.3%

Shares of ARCT opened at $11.86 on Wednesday. Arcturus Therapeutics Holdings Inc. has a 12-month low of $8.04 and a 12-month high of $45.00. The firm has a market cap of $321.66 million, a P/E ratio of -5.34 and a beta of 2.36. The company’s 50-day moving average price is $11.78 and its 200 day moving average price is $15.38.

Arcturus Therapeutics (NASDAQ:ARCT) last released its earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($1.58) by $1.06. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The company had revenue of $29.38 million during the quarter, compared to the consensus estimate of $25.64 million. Equities research analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ARCT. BTIG Research set a $48.00 price objective on Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Canaccord Genuity Group dropped their price objective on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a “buy” rating for the company in a report on Tuesday. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. Finally, Wells Fargo & Company decreased their target price on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Arcturus Therapeutics presently has an average rating of “Buy” and an average price target of $58.80.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.